1346 related articles for article (PubMed ID: 11152019)
1. Delavirdine: a review of its use in HIV infection.
Scott LJ; Perry CM
Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019
[TBL] [Abstract][Full Text] [Related]
2. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
3. Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.
Figgitt DP; Plosker GL
Drugs; 2000 Aug; 60(2):481-516. PubMed ID: 10983742
[TBL] [Abstract][Full Text] [Related]
4. Didanosine: an updated review of its use in HIV infection.
Perry CM; Noble S
Drugs; 1999 Dec; 58(6):1099-135. PubMed ID: 10651392
[TBL] [Abstract][Full Text] [Related]
5. Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed.
Bellman PC
AIDS; 1998 Jul; 12(11):1333-40. PubMed ID: 9708413
[TBL] [Abstract][Full Text] [Related]
6. Nelfinavir. A review of its therapeutic efficacy in HIV infection.
Jarvis B; Faulds D
Drugs; 1998 Jul; 56(1):147-67. PubMed ID: 9664204
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.
Grodesky M; Acosta EP; Fujita N; Mason S; Gerber JG
HIV Clin Trials; 2001; 2(3):193-9. PubMed ID: 11590527
[TBL] [Abstract][Full Text] [Related]
8. Abacavir: a review of its clinical potential in patients with HIV infection.
Hervey PS; Perry CM
Drugs; 2000 Aug; 60(2):447-79. PubMed ID: 10983741
[TBL] [Abstract][Full Text] [Related]
9. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.
Barry M; Mulcahy F; Merry C; Gibbons S; Back D
Clin Pharmacokinet; 1999 Apr; 36(4):289-304. PubMed ID: 10320951
[TBL] [Abstract][Full Text] [Related]
11. Delavirdine: clinical pharmacokinetics and drug interactions.
Tran JQ; Gerber JG; Kerr BM
Clin Pharmacokinet; 2001; 40(3):207-26. PubMed ID: 11327199
[TBL] [Abstract][Full Text] [Related]
12. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
[TBL] [Abstract][Full Text] [Related]
13. Initial therapy with protease inhibitor-sparing regimens: evaluation of nevirapine and delavirdine.
Conway B
Clin Infect Dis; 2000 Jun; 30 Suppl 2():S130-4. PubMed ID: 10860897
[TBL] [Abstract][Full Text] [Related]
14. Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection.
Bhana N; Ormrod D; Perry CM; Figgitt DP
Paediatr Drugs; 2002; 4(8):515-53. PubMed ID: 12126455
[TBL] [Abstract][Full Text] [Related]
15. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial.
Been-Tiktak AM; Boucher CA; Brun-Vezinet F; Joly V; Mulder JW; Jost J; Cooper DA; Moroni M; Gatell JM; Staszewski S; Colebunders R; Stewart GJ; Hawkins DA; Johnson MA; Parkin JM; Kennedy DH; Hoy JF; Borleffs JC
Int J Antimicrob Agents; 1999 Jan; 11(1):13-21. PubMed ID: 10075273
[TBL] [Abstract][Full Text] [Related]
17. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
18. Nelfinavir: an update on its use in HIV infection.
Bardsley-Elliot A; Plosker GL
Drugs; 2000 Mar; 59(3):581-620. PubMed ID: 10776836
[TBL] [Abstract][Full Text] [Related]
19. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884.
Fletcher CV; Acosta EP; Cheng H; Haubrich R; Fischl M; Raasch R; Mills C; Hu XJ; Katzenstein D; Remmel RP; Gulick RM;
AIDS; 2000 Nov; 14(16):2495-501. PubMed ID: 11101060
[TBL] [Abstract][Full Text] [Related]
20. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
